Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us

Session 96   Poster Abstracts
Prevalence of Drug Resistance: Cohort Studies
Monday, 1:30 - 3:30 pm
Poster Hall
686The Influence of the Widespread Use of ART on HIV-1 pol Evolution
R Pilon*1, A Burchell2, S Read3, L Calzavara2, P Sandstrom1, and The Polaris HIV Study Team
1Hlth. Canada, Ottawa, Canada; 2Univ. of Toronto, Canada; and 3Hosp. for Sick Children, Toronto, Canada
687
A Dynamic Analysis that Allows More Accurate Estimates of the Prevalence of Mutations in ART-naive HIV/AIDS Patients in a UK Cohort (January 2001 to Date)
C Loveday1, E MacRae*1, M Johnson2, and on behalf of the ICVC Collaborative Research Group1
1Intl. Clin. Virology Ctr., Buckinghamshire, UK and 2Royal Free Ctr. for HIV Med., London, UK
688
Analysis of Genotypic Resistance of HIV- 1 Isolates from >400 Untreated Individuals Recruited in West Africa and South East Asia (ANRS 1257 Project): An Overview of the Data Available
H J Fleury*1, T Toni2, and N T H Lan3
1Univ. of Bordeaux2, France; 2CIRBA and CeDRes, Abidjan, Ivory Coast; and 3Direction of Hlth. Svc., Ho Chi Minh City, Vietnam
689HIV Drug Resistance in a Large Clinical Cohort--Effect of Initial Triple Therapy Regimen on Time Course of Selection of Resistance Mutations
P R Harrigan*, W Dong, J Asselin, C Alexander, T Mo, B Wynhoven, Z Brumme, R Hogg, and J S G Montaner
British Columbia Ctr. for Excellence in HIV/AIDS, Vancouver, Canada
690
High-level Dual and Triple Class Multi-drug Resistance in a Large Health Maintenance Organization: Prevalence, Risk Factors, and Response to Salvage Therapy
W J Fessel*1, SY Rhee2, L Hurley1, D P Nguyen1, S Slome1, S Smith1, D Klein1, M Horberg1, J Flamm1, S Follansbee1, M J Gonzales2, and R W Shafer2
1Kaiser Permanente Med. Care Prgm. of Northern California, USA and 2Stanford Univ., CA, USA